ResearcherShanghai Medical College of Fudan UniversityNo recent work listed
Jian-ang Li
Matched on OpenAlex author ID A5059343123. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 3
- DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. Co-author DOI 10.1111/jcmm.16196↗
- Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
- Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Co-author DOI 10.1080/15384101.2017.1405194↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yefei Rong · 3 shared papers, 2018–2021 · strength 0.27
- Paper DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. DOI 10.1111/jcmm.16196↗
- Paper Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. DOI 10.1016/j.canlet.2019.06.013↗
- Paper Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. DOI 10.1080/15384101.2017.1405194↗
- Tiantao Kuang · 3 shared papers, 2018–2021 · strength 0.27
- Paper DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. DOI 10.1111/jcmm.16196↗
- Paper Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. DOI 10.1016/j.canlet.2019.06.013↗
- Paper Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. DOI 10.1080/15384101.2017.1405194↗
- Dansong Wang · 2 shared papers, 2018–2019 · strength 0.16
- Wenhui Lou · 1 shared paper, 2021 · strength 0.12
- Xu Han · 1 shared paper, 2021 · strength 0.12
- Yuan Fang · 1 shared paper, 2021 · strength 0.12
- Zhi Li · 1 shared paper, 2021 · strength 0.12
- Xuefeng Xu · 1 shared paper, 2019 · strength 0.08
- Yuan Fang · 1 shared paper, 2019 · strength 0.08
- Ning Pu · 1 shared paper, 2019 · strength 0.08
- Hanlin Yin · 1 shared paper, 2019 · strength 0.08
- Shanshan Gao · 1 shared paper, 2019 · strength 0.08
- Wenhui Lou · 1 shared paper, 2019 · strength 0.08
- Dayong Jin · 1 shared paper, 2019 · strength 0.08
- Jun Yu · 1 shared paper, 2019 · strength 0.08
- Wenchuan Wu · 1 shared paper, 2019 · strength 0.08
- Zhenkun Lou · 1 shared paper, 2018 · strength 0.07
- Chao Song · 1 shared paper, 2018 · strength 0.07
- Wenhui Lou · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.